A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer

Cited 13 time in webofscience Cited 0 time in scopus
  • Hit : 464
  • Download : 510
DC FieldValueLanguage
dc.contributor.authorLee, Hyunseungko
dc.contributor.authorLi, Guang-Yongko
dc.contributor.authorJeong, Yujeongko
dc.contributor.authorJung, Kyung Heeko
dc.contributor.authorLee, Ju-Heeko
dc.contributor.authorHam, Kyungrokko
dc.contributor.authorHong, Sungwooko
dc.contributor.authorHong, Soon-Sunko
dc.date.accessioned2013-03-11T03:36:59Z-
dc.date.available2013-03-11T03:36:59Z-
dc.date.created2012-04-20-
dc.date.created2012-04-20-
dc.date.issued2012-05-
dc.identifier.citationCANCER LETTERS, v.318, no.1, pp.68 - 75-
dc.identifier.issn0304-3835-
dc.identifier.urihttp://hdl.handle.net/10203/98162-
dc.description.abstractPotentiation of anti-breast cancer activity of an imidazopyridine-based PI3K alpha inhibitor, HS-104, was investigated in human breast cancer cells. HS-104 shows strong inhibitory activity against recombinant PI3K alpha isoform and the PI3K signaling pathway, resulting in anti-proliferative activity in breast cancer cells. It also induced cell cycle arrest at the G(2)/M phase as well as apoptosis. Furthermore, oral administration of HS-104 significantly inhibited the growth of tumor in SkBr3 mouse xenograft models. Therefore, HS-104 could be considered as a potential candidate for the treatment of human breast cancer. Crown Copyright (C) 2011 Published by Elsevier Ireland Ltd. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER IRELAND LTD-
dc.subjectVIVO ANTITUMOR-ACTIVITY-
dc.subjectIN-VIVO-
dc.subjectCELL-PROLIFERATION-
dc.subjectPATHWAY-
dc.subjectPTEN-
dc.subjectPHOSPHORYLATION-
dc.subjectMUTATIONS-
dc.subjectCARCINOMA-
dc.subjectSURVIVAL-
dc.subjectKINASE-
dc.titleA novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer-
dc.typeArticle-
dc.identifier.wosid000301624300009-
dc.identifier.scopusid2-s2.0-84857140273-
dc.type.rimsART-
dc.citation.volume318-
dc.citation.issue1-
dc.citation.beginningpage68-
dc.citation.endingpage75-
dc.citation.publicationnameCANCER LETTERS-
dc.identifier.doi10.1016/j.canlet.2011.12.001-
dc.contributor.localauthorHong, Sungwoo-
dc.contributor.nonIdAuthorLee, Hyunseung-
dc.contributor.nonIdAuthorLi, Guang-Yong-
dc.contributor.nonIdAuthorJung, Kyung Hee-
dc.contributor.nonIdAuthorLee, Ju-Hee-
dc.contributor.nonIdAuthorHam, Kyungrok-
dc.contributor.nonIdAuthorHong, Soon-Sun-
dc.type.journalArticleArticle-
dc.subject.keywordAuthorPI3K-
dc.subject.keywordAuthormTOR-
dc.subject.keywordAuthorApoptosis-
dc.subject.keywordAuthorBreast cancer-
dc.subject.keywordPlusVIVO ANTITUMOR-ACTIVITY-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusCELL-PROLIFERATION-
dc.subject.keywordPlusPATHWAY-
dc.subject.keywordPlusPTEN-
dc.subject.keywordPlusPHOSPHORYLATION-
dc.subject.keywordPlusMUTATIONS-
dc.subject.keywordPlusCARCINOMA-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusKINASE-
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 13 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0